Literature DB >> 1662633

High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose.

D L Morris1, A De Souza, J A Jones, W E Morgan.   

Abstract

Antibiotic concentrations in pulmonary tissue samples and plasma were studied in this open investigation. Twenty-nine patients scheduled for elective pulmonary surgery received a single oral dose of 500 mg azithromycin 24, 72, 96 or 120 h prior to the operation; two patients received 250 mg b.i.d. Blood samples were taken before and at the time of resection, and tissue was obtained during surgery. Plasma and tissue concentrations of azithromycin were measured by high performance liquid chromatography (HPLC) and a microbiological bioassay. Only one patient had a detectable plasma concentration of azithromycin (0.13 micrograms/ml), measured 24 h post-dose by HPLC. However, high and sustained levels were found in lung tissue: mean concentrations measured by HPLC were 3.10 micrograms/g (SD +/- 2.17), 2.55 micrograms/g (SD +/- 1.36), 3.94 micrograms/g (SD +/- 2.40) and 3.13 micrograms/g (SD +/- 0.50) at 24, 72, 96 and 120 h, respectively. Bioassay results were similar to those for the HPLC assay. In summary, azithromycin levels in pulmonary tissue remained close to 3 micrograms/g for up to 5 days after a single oral 500 mg dose, in contrast to plasma levels which were much lower. The lung concentrations found are inhibitory for many sensitive respiratory pathogens and short-course azithromycin therapy is therefore a possibility.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1662633     DOI: 10.1007/bf01975842

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  6 in total

1.  Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias.

Authors:  S Schönwald; M Gunjaca; L Kolacny-Babić; V Car; M Gosev
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

2.  Comparative studies of azithromycin in skin and soft-tissue infections and sexually transmitted infections by Neisseria and Chlamydia species.

Authors:  A Lassus
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

3.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

4.  Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides.

Authors:  G M Bright; A A Nagel; J Bordner; K A Desai; J N Dibrino; J Nowakowska; L Vincent; R M Watrous; F C Sciavolino; A R English
Journal:  J Antibiot (Tokyo)       Date:  1988-08       Impact factor: 2.649

5.  Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

Authors:  D J Hardy; D M Hensey; J M Beyer; C Vojtko; E J McDonald; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

6.  Azithromycin concentrations at the sites of pulmonary infection.

Authors:  D R Baldwin; R Wise; J M Andrews; J P Ashby; D Honeybourne
Journal:  Eur Respir J       Date:  1990-09       Impact factor: 16.671

  6 in total
  14 in total

1.  Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin.

Authors:  Masami Sugie; Emiko Asakura; Ying Lan Zhao; Shoko Torita; Masayuki Nadai; Kenji Baba; Kiyoyuki Kitaichi; Kenji Takagi; Kenzo Takagi; Takaaki Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases.

Authors:  Itsuro Kazama; Tsutomu Tamada; Masahiro Tachi
Journal:  Inflamm Res       Date:  2015-07-24       Impact factor: 4.575

3.  Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.

Authors:  P Matzneller; S Krasniqi; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

4.  Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers.

Authors:  K A Rodvold; M H Gotfried; L H Danziger; R J Servi
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

5.  The effect of azithromycin on the maturation and function of murine bone marrow-derived dendritic cells.

Authors:  S Iwamoto; T Kumamoto; E Azuma; M Hirayama; M Ito; K Amano; M Ido; Y Komada
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

Review 6.  Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections.

Authors:  C J Dunn; L B Barradell
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

7.  Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team.

Authors:  L Y Ngo; R Yogev; W M Dankner; W T Hughes; S Burchett; J Xu; B Sadler; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

Review 8.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

9.  Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.

Authors:  Keith A Rodvold; Larry H Danziger; Mark H Gotfried
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 10.  Azithromycin clinical pharmacokinetics.

Authors:  N J Lalak; D L Morris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.